Respiratory syncytial virus (RSV) is one of the single most important causes of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly and immunocompromised patients; it is associated with significant morbidity and mortality in these populations.
However, RSV is recognised as a significant cause of respiratory illness in all age groups and there are no effective licensed therapies generally available. Novel correlates of protection are being explored and developing vaccine correlates can assist to bridging other populations. Healthy volunteer human challenge models will play a major role in the development process.
Healthy volunteers 18-55 year old
Older Adults aged 60-75 years old
Conducted a number of human RSV challenge studies for a range of customers:
As the industry leader in conducting human viral challenge studies, we have developed a large Virobase, of clinical data paired with virological data, host genetics and immunology combined with an extensive biorepository of blood and respiratory samples. This “Virometrics” resource, in conjunction with our unique insight into the host response to viral disease, allows us to tailor study designs to each IMP.
Study design matched to investigational product mechanism of actions
